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The consideration of a sentinel lymph node
biopsy (SLNB) in patients with clinically node-
negative high-risk primary cutaneous squamous
cell carcinoma (cSCC) remains challenging. A
paucity of evidence to guide clinicians results in
varied management practices.1 Recently, the
Brigham and Women’s Hospital Tumor (BWH-T)
staging for cSCC was proposed and seems to more
precisely identify possible candidates for sentinel
lymph node biopsy.2-4 We present a patient with a
history of a double lung and renal transplantation
with an aggressive cSCC who had a positive SNLB.
We discuss considerations of a SLNB as it relates to
solid organ transplant recipients (SOTRs) with cSCC.
CASE REPORT
A 50-year-old man with a medical history of a
double lung transplant for chronic obstructive
pulmonary disease 2 years prior and a kidney trans-
plant for cyclosporine-induced nephrotoxicity was
referred to the dermatology department for
evaluation of a lesion involving his nasal tip. His
medications included azathioprine, cyclosporine,
prednisone, voriconazole, and warfarin. He had no
personal or family history of skin cancer.
He noticed the lesion 3 months before presenta-
tion and reported it was growing and intermittently
bleeding. On examination, a 1-cm ulcerated
erythematous nodule was noted on his nasal tip. A
shave biopsy found cSCC with ulceration and
impetiginization.
Definitive surgical management was delayed by
multiple hospitalizations for, among other things,the Department of Dermatologya and Division of Dermato-
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905. E-mail: lopez.jonathan@mayo.edu.acute purulent cholecystitis requiring cholecystec-
tomy and thrombosis of his allograft renal vein and
inferior vena cava requiring percutaneous mechan-
ical thrombectomy.
The patient returned for Mohs micrographic
surgery 3 months after the initial biopsy, by which
time the tumor had enlarged to 2 cm and was
ulcerated (Fig 1). There were no intransit metastases
or lymphadenopathy on examination. Frozen sec-
tions showed moderate differentiation, perineural
invasion, and extension to cartilage. Removal of
small portions of the septal cartilage, upper lateral
nasal cartilages, and part of the dome of the lower
lateral alar cartilages was required to obtain histo-
logic tumor-free margins. The resulting defect
measured 4.53 4.0 cm. Reconstruction was delayed
for further evaluation and staging.
Positron emission tomography and computed
tomography scanning found no evidence of local,
regional, or metastatic disease. The patient was
referred to otorhinolaryngology where a safety
margin was obtained because of the highly aggres-
sive features of the tumor. No residual tumor was
identified in the safety margin. The resulting defect
was reconstructed with a paramedian forehead flap.
Sentinel node lymphoscintigraphy found drainage to
3 sentinel nodes: a left neck lymph node, a right neckJAAD Case Reports 2015;1:S2-4.
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Fig 1. Two-centimeter cSCC with ulceration on the nasal
tip before Mohs micrographic surgery.
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One of 3 lymph nodes (left side of the neck) was
positive for grade 2 (of 4, moderately differentiated)
squamous cell carcinoma, and a level I through III
left neck dissection was completed. No additional
lymph nodes were positive for malignancy.
The radiation oncology department recommen-
ded adjuvant external beam radiation therapy. The
patient elected not to complete radiation therapy.
The patient tolerated the procedures well until
shortly after the takedown of the paramedian fore-
head flap. The patient’s wife was concerned that the
patient was becoming depressed, not eating, and
drinking only minimal fluids. The patient denied
suicidal ideation. Several attempts were made to
convince the patient to return for further evaluation.
Ten days after the paramedian forehead flap take-
down (approximately 5 months after his initial pre-
sentation to the dermatology clinic) the patient died
of unknown causes at his home.DISCUSSION
In this case, a SOTR with an aggressive cSCC
underwent SLNB, which found metastatic disease in
one lymph node. He had been on voriconazole for
19 months before the initial consultation in July 2005.
More than a year later, the first suggestion of a link
between voriconazole and cSCC was reported.5
Voriconazole was continued through the course.
This tumor would be staged as a T2 lesion in the
American Joint Committee on Cancer seventh edi-
tion staging system (perineural invasion and Clark
level $ IV) and a T2b lesion in the BWH-T staging
system (tumor diameter $ 2 cm, perineural invasion
$ 0.1 mm, and tumor invasion beyond fat).2,6Although SLNB is safe and is used to identify occult
nodal disease, this case highlights knowledge gaps in
our understanding of nodal staging for cSCC.7 The
use of SLNB, although useful in staging disease in this
patient, should not be considered the standard of
care but should be considered on a case-by-case
basis.
One knowledge gap is the proper identification of
patients for whom SLNB be considered and offered.
The BWH-T staging system appears to stratify disease
by the risk of nodal metastasis with rates of 21% and
67% for T2b and T3 tumors, respectively.3 The
validity of this staging system was supported by a
meta-analysis of sentinel lymph node biopsy rates
according to tumor stage.4 Although these data have
provided some clarity on proper patient selection,
further validation of the staging system is necessary.
A second knowledge gap is the sensitivity and
specificity of SLNB for patients whose disease is
staged with an increased risk of nodal metastasis. A
recent systematic review of cSCC of the head and
neck identified 73 patients and suggests the false
omission rate (regional recurrence in a nodal basin
found to be negative on prior SLNB) to be approx-
imately 5% (similar to melanoma).8 Additional pro-
spective trials with appropriate follow-up are
needed to elucidate the accuracy of this diagnostic
procedure. A third knowledge gap is the relationship
between SLNB results for cSCC and patient out-
comes. Although it seems biologically plausible that
early intervention of occult nodal disease will
improve patient outcomes, the data to support or
refute this assumption are currently lacking.
While we await data for the gaps listed above,
clinicians must use their clinical judgement and the
available data to provide patient care. Despite worse
outcomes of cSCC in SOTRs, neither the American
Joint Committee on Cancer nor BWH-T staging
systems consider immunosuppression or a history
of organ transplant when staging disease.9 With this
background and the currently available data, we
recommend using the BWH-T staging system and
considering SLNB in SOTR with $T2b tumors until
more data are collected.
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